Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: AI
Statins have long had the job of lowering LDL cholesterol and protecting the heart. But new a study has emerged stating that these medicines may have another significant benefit for the brain.
A 15-year Danish study involving more than 132,000 people with type 2 diabetes found that those who started taking statins earlier had a 15% lower risk of developing dementia compared with those who started treatment later. Even later, statin use was associated with a 10% lower risk.
The researchers suggest that the timing of treatment is key as prolonged exposure to high cholesterol and other cardiovascular risk factors could contribute to damage that accumulate over many years.
The findings, presented at the European Society of Cardiology Congress and published in The Lancet Regional Health – Europe, come as researchers are constantly exploring the connection between cholesterol, blood vessels, and brain health.
The brain is an enormous delivery network in which billions of cells depend on a constant supply of oxygen and nutrients delivered through tiny blood vessels.
High levels of LDL cholesterol can contribute to atherosclerosis, where fatty deposits build up inside arteries. Over time, this can damage blood vessels and restrict blood flow.
Damage to the brain's blood vessels can contribute to vascular cognitive impairment and vascular dementia, while strokes can also increase the risk of subsequent cognitive decline.
Also read: Hormone Replacement Therapy May Lower Dementia Risk In Women, Shows Study
This study merely observed the correlation between statins and dementia risk, meaning it did not establish a definite cause-and-effect relationship. People who start statins earlier may also differ from those who start later in other ways, including their overall management of diabetes and cardiovascular risk.
The researchers therefore say more work is needed to determine whether statins have a direct protective effect on the brain.
Also read: Bruce Willis’ Daughter Rumer Undergoes ‘Terrifying’ Genetic Tests Amid Dad’s Dementia Diagnosis
It is important to note the difference between treating unhealthy LDL cholesterol levels and assuming that everyone should aggressively lower cholesterol to prevent dementia. Statins remain as the medication to reduce cardiovascular risk.
Their potential brain benefits are an additional area of research. So, people must not blindly start popping statins to lower the risk of neurodegenerative diseases like dementia.
There is another reassuring point for people already taking statins. The concerns that these medicines may result in the increase of dementia risk have not been supported by the strongest available evidence.
A large review of randomised trials earlier this year found that most reported statin side effects were no more common than with placebo, including reported memory problems.
The most interesting takeaway may not be that “statins prevent dementia.” The evidence isn't strong enough to make that claim yet. It is that heart health and brain health are deeply intertwined.
Managing cholesterol, blood pressure, diabetes and other cardiovascular risk factors, along with regular physical activity and a healthy diet, may help protect the blood vessels that keep the brain functioning.
Credit: AI
The Maharashtra Food and Drug Administration (FDA) has recently sparked headlines for bringing several known brands under its tight scrutiny. Cipla was one of them after the drug regulator cancelled one of its facility’s licenses over alleged violations associated with Reactin Plus tablets.
Soon after that, the Bombay High Court questioned the manner in which the action was taken, prompting the Maharashtra Food and Drug Administration (FDA) to withdraw its cancellation order.
The dispute has now become more about how far a regulator can go while enforcing drug safety rules, and whether due process was followed before cancelling the license.
Maharashtra FDA recently conducted an inspection of Cipla Pharma & Life Sciences’ carrying and forwarding facility at Wadki in Pune.
During an inspection in June, FDA officials found that the packaging of Reactin Plus, a Schedule H prescription medicine, described it as an “analgesic and antipyretic”. The FDA said this amounted to unauthorised advertising of a prescription drug and violated provisions of the Drugs and Cosmetics Act and Rules.
The regulator seized Reactin Plus stock worth around Rs 11.19 lakh and instructed that the product be recalled.
But the FDA said the recall directions were not fully complied with. A subsequent inspection also found discrepancies between physical stock, computerised records and purchase and sales data.
Medicines were reportedly found stored directly on the floor, with inadequate proper storage arrangements. Deficiencies were also identified in the handling of expired medicines.
Based on these findings, the FDA cancelled the drug-sale licenses of the facility with effect from August 27.
Maharashtra FDA Commissioner Tukaram Mundhe said, “The Food and Drug Administration will not show any leniency regarding the safety of medicines and the health of citizens.”
He added, “Any entity within the pharmaceutical manufacturing and distribution system found violating regulations will face stringent legal action.”
Cipla challenged FDA's action before the Bombay High Court. On August 30, the court criticised the regulator's approach, describing it as “high-handed” and saying the FDA had gone “overboard”. The court also questioned whether the principles of natural justice had been followed.
During the hearing, the court asked, “Do you feel you are a Lord and you can do anything?”
The court's concern was not necessarily that the FDA should not regulate Cipla. Instead, it questioned the manner and procedure through which the license was cancelled.
Following the court's intervention, the Maharashtra FDA withdrew the cancellation order and said it would issue a fresh show-cause notice before passing an order.
So, the license has been restored for now, but that does not mean the underlying regulatory concerns have disappeared.
Also read: Everest Hing Sale Prohibited By FSSAI; 3 Other Masalas Flagged For Violations
Cipla has maintained that the matter is under judicial consideration and therefore declined to comment in detail. The company said the FDA order relates to the operations of a C&F warehouse, rather than allegations concerning the medicine's safety or effectiveness.
According to mint, Cipla said, “Cipla has been a trusted healthcare organization for nine decades and continues to uphold the highest standards of quality, regulatory compliance, and patient safety.”
The company also clarified that the FDA order “does not allege any concerns relating to the safety, quality or efficacy of its products”.
The FDA action focuses on violations related to labelling, recall compliance, storage, inventory records and distribution practices.
It did not establish that Reactin Plus was unsafe, ineffective, or contaminated. Cipla has specifically said the order did not concern the product's safety, quality, or efficacy.
Credit: AI
One of the country's most popular condiment brands, Everest, is under tight FSSAI scrutiny after the food regulator ordered a temporary ban of sale of its hing (asafoetida) and a few masalas.
The Food Safety and Standards Authority of India (FSSAI) has prohibited the sale of compounded hing manufactured by Everest Food Products and Laljee Godhoo and Company after laboratory testing found samples that did not meet food safety standards.
The regulator has spotted compliance issues in three Everest spice blends. They include egg curry masala, chicken masala, and its widely sold garam masala.
To clarify, the three Everest masalas have not been banned permanently. They have been flagged for non-compliance, and the company has been asked to explain the violations and submit an action plan to resolve the said issues.
The action against hing came after a consumer complaint that prompted FSSAI to begin surveillance of major hing brands.
Samples were collected from Everest's facility in Mumbai and its manufacturing unit in Umbergaon, Gujarat, to be sent for laboratory testing.
According to FSSAI, its compounded hing samples tested contained only 0% to 3% alcohol-soluble extract, despite the prescribed minimum being 5%.
Compounded hing, which is not pure raw asafoetida, is a regulated food product made by blending raw hing with other ingredients like starches, flour, and gum Arabic. The required alcohol-soluble extract helps establish whether sufficient raw asafoetida is present in the final product.
FSSAI said the test results indicated that the products contained 30% to 40% less raw hing than required.
The regulator also found a separate problem in six varieties of raw hing tested at the Laljee Godhoo facility. Their starch content ranged between 15% and 32%, while the permitted maximum is 1%.
The regulator also detected non-compliance in Everest egg curry masala, chicken masala, and garam masala. However, unlike the hing products, these three spice blends have not been prohibited from sale.
The companies have been asked to explain the violations and submit action plans elaborating how they intend to comply with the food safety standards.
FSSAI has also advised the manufacturers to voluntarily recall substandard hing products already in the market.
Also read: US FDA Recalls Injectables Over Fiberglass, Steel Particles: See Affected Drugs
FSSAI's action is a preventive food safety measure. The regulator said the manufacturers must address the violations and ensure their compounded hing meets the prescribed standards. The prohibition on the product will remain in place until compliance requirements are met.
For consumers, the episode also highlights the fact how food adulteration or substandard manufacturing is not always visible to the naked eye. A spice may look, smell and taste perfectly fine while still failing a major food safety standard.
Laboratory testing is therefore crucial for identifying problems like incorrect composition or inadequate levels of the ingredient in a product.
This comes at a time when FSSAI is tightening rules over food standards and labelling. Just days ago, the regulator proposed hexagonal red, front-of-pack warning labels for packaged junk foods that are high in sugar, salt or saturated fats. It told the Supreme Court that the aim is to make such information easier for consumers to understand.
© 2024 Bennett, Coleman & Company Limited